300832.SZ
Shenzhen New Industries Biomedical Engineering Co., Ltd. [300832.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
300832.SZ Stock Summary
Top 10 Correlated ETFs
300832.SZ
Top 10 Correlated Stocks
300832.SZ
In the News
300832.SZ Financial details
Company Rating
Strong Buy
Market Cap
51.71B
Income
1.59B
Revenue
3.66B
Book val./share
9.04
Cash/share
4.14
Dividend
0.7
Dividend %
0.96%
Employees
2.63K
Optionable
No
Shortable
Yes
Earnings
26 Apr 2024
P/E
36.07
Forward P/E
-
PEG
5.73
P/S
15.68
P/B
8.08
P/C
15.35
P/FCF
52.27
Quick Ratio
7.06
Current Ratio
9.39
Debt / Equity
0
LT Debt / Equity
0
-
-
EPS (TTM)
2.02
EPS next Y
-
EPS next Q
-
EPS this Y
36.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
11.29%
Revenue last 5Y
17.1%
Revenue Q/Q
5.42%
EPS Q/Q
12%
-
-
-
-
SMA20
-18.84%
SMA50
-9.63%
SMA100
-2.41%
Inst Own
-
Inst Trans
-
ROA
21%
ROE
24%
ROC
0.25%
Gross Margin
72%
Oper. Margin
49%
Profit Margin
43%
Payout
35%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
49.86-83.5
52W High
-23.43%
52W Low
+29.69%
RSI
28.34
Rel Volume
1.82
Avg Volume
3.08M
Volume
5.61M
Perf Week
-3.86%
Perf Month
-21.18%
Perf Quarter
2.82%
Perf Half Y
1.03%
-
-
-
-
Beta
-0.612
-
-
Volatility
1.62%, 6.99%
Prev Close
-3.49%
Price
63.55
Change
-3.42%
300832.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.97 | 2.15 | 2.81 | 3.25 | 3.88 | |
| Net income per share | 0.99 | 0.99 | 1.2 | 1.24 | 1.69 | |
| Operating cash flow per share | 1 | 1.06 | 1.25 | 0.99 | 1.22 | |
| Free cash flow per share | 0.59 | 0.65 | 0.92 | 0.55 | 0.71 | |
| Cash per share | 2.03 | 2.53 | 4.32 | 4.37 | 4.2 | |
| Book value per share | 3.36 | 4.01 | 6.14 | 7.16 | 8.14 | |
| Tangible book value per share | 3.28 | 3.88 | 6.02 | 7.04 | 7.93 | |
| Share holders equity per share | 3.36 | 4.01 | 6.14 | 7.16 | 8.14 | |
| Interest debt per share | 0 | -0.06 | 0.08 | 0 | 0 | |
| Market cap | 16.74B | 18.6B | 54.36B | 34.53B | 39.4B | |
| Enterprise value | 15.31B | 16.62B | 53.34B | 33.92B | 38.91B | |
| P/E ratio | 24.12 | 24.08 | 57.88 | 35.47 | 29.67 | |
| Price to sales ratio | 12.1 | 11.06 | 24.76 | 13.57 | 12.93 | |
| POCF ratio | 23.85 | 22.37 | 55.66 | 44.66 | 40.94 | |
| PFCF ratio | 40.14 | 36.87 | 75.3 | 80.26 | 70.45 | |
| P/B Ratio | 7.08 | 5.93 | 11.31 | 6.15 | 6.16 | |
| PTB ratio | 7.08 | 5.93 | 11.31 | 6.15 | 6.16 | |
| EV to sales | 11.07 | 9.89 | 24.3 | 13.33 | 12.77 | |
| Enterprise value over EBITDA | 17.75 | 17.74 | 45.94 | 28.12 | 24.08 | |
| EV to operating cash flow | 21.81 | 19.99 | 54.62 | 43.87 | 40.44 | |
| EV to free cash flow | 36.71 | 32.94 | 73.9 | 78.83 | 69.59 | |
| Earnings yield | 0.04 | 0.04 | 0.02 | 0.03 | 0.03 | |
| Free cash flow yield | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0 | -0.01 | 0.01 | 0 | 0 | |
| Debt to assets | 0 | -0.01 | 0.01 | 0 | 0 | |
| Net debt to EBITDA | -1.66 | -2.11 | -0.87 | -0.51 | -0.3 | |
| Current ratio | 7.07 | 8.06 | 8.37 | 8.85 | 8.26 | |
| Interest coverage | 697.01 | 0 | 955.49 | 7.45K | 5.47K | |
| Income quality | 1.01 | 1.08 | 1.04 | 0.79 | 0.72 | |
| Dividend Yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.15 | 0 | 0.66 | 0.42 | 0.36 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.06 | 0.07 | 0.07 | 0.08 | 0.1 | |
| Intangibles to total assets | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.41 | -0.39 | -0.26 | -0.44 | -0.42 | |
| Capex to revenue | -0.21 | -0.19 | -0.12 | -0.13 | -0.13 | |
| Capex to depreciation | -7.2 | -6.18 | -3.22 | -3.54 | -3.46 | |
| Stock based compensation to revenue | 0 | 0 | 0.06 | 0.04 | -0.03 | |
| Graham number | 8.64 | 9.45 | 12.88 | 14.14 | 17.6 | |
| ROIC | 0.29 | 0.25 | 0.19 | 0.17 | 0.21 | |
| Return on tangible assets | 0.27 | 0.23 | 0.18 | 0.16 | 0.19 | |
| Graham Net | 2.02 | 2.51 | 4.2 | 4.41 | 4.43 | |
| Working capital | 1.6B | 2.18B | 3.63B | 3.99B | 4.24B | |
| Tangible asset value | 2.31B | 3.04B | 4.71B | 5.52B | 6.23B | |
| Net current asset value | 1.59B | 2.17B | 3.62B | 3.97B | 4.21B | |
| Invested capital | 0 | -0.01 | 0.01 | 0 | 0 | |
| Average receivables | 216.25M | 236.76M | 245.29M | 278.48M | 410.49M | |
| Average payables | 71.83M | 58.37M | 76.22M | 134.81M | 174.02M | |
| Average inventory | 168.75M | 215.59M | 348.03M | 552.33M | 742.35M | |
| Days sales outstanding | 59.5 | 53.83 | 40.34 | 45.08 | 60.69 | |
| Days payables outstanding | 86.01 | 58.67 | 71.61 | 85.17 | 71.16 | |
| Days of inventory on hand | 267.29 | 256.44 | 334.7 | 320.8 | 338.06 | |
| Receivables turnover | 6.13 | 6.78 | 9.05 | 8.1 | 6.01 | |
| Payables turnover | 4.24 | 6.22 | 5.1 | 4.29 | 5.13 | |
| Inventory turnover | 1.37 | 1.42 | 1.09 | 1.14 | 1.08 | |
| ROE | 0.29 | 0.25 | 0.2 | 0.17 | 0.21 | |
| Capex per share | -0.4 | -0.42 | -0.33 | -0.44 | -0.51 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.12 | 0.95 | 1.11 | 1.26 | 1.33 | |
| Net income per share | 0.45 | 0.51 | 0.45 | 0.5 | 0.56 | |
| Operating cash flow per share | 0.45 | 0.51 | 0.45 | 0.44 | 0.51 | |
| Free cash flow per share | 0.36 | 0.32 | 0.34 | 0.3 | 0.44 | |
| Cash per share | 4 | 4.2 | 4.36 | 3.9 | 4.14 | |
| Book value per share | 7.79 | 8.14 | 8.6 | 8.46 | 9.04 | |
| Tangible book value per share | 7.67 | 7.93 | 8.38 | 8.24 | 8.82 | |
| Share holders equity per share | 7.79 | 8.14 | 8.6 | 8.46 | 9.04 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0.01 | |
| Market cap | 29.6B | 39.4B | 48.06B | 46.36B | 49.91B | |
| Enterprise value | 28.56B | 38.91B | 47.36B | 45.83B | 49.11B | |
| P/E ratio | 20.84 | 24.42 | 33.84 | 29.35 | 28.57 | |
| Price to sales ratio | 33.64 | 52.51 | 54.87 | 46.86 | 47.85 | |
| POCF ratio | 83.37 | 97.67 | 135.36 | 133.62 | 124.61 | |
| PFCF ratio | 104.7 | 157.01 | 181.94 | 193.9 | 145.46 | |
| P/B Ratio | 4.84 | 6.16 | 7.12 | 6.97 | 7.03 | |
| PTB ratio | 4.84 | 6.16 | 7.12 | 6.97 | 7.03 | |
| EV to sales | 32.46 | 51.87 | 54.08 | 46.33 | 47.09 | |
| Enterprise value over EBITDA | 69.12 | 91.74 | 118.99 | 98.81 | 101.82 | |
| EV to operating cash flow | 80.45 | 96.48 | 133.4 | 132.11 | 122.61 | |
| EV to free cash flow | 101.03 | 155.09 | 179.3 | 191.71 | 143.12 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -2.51 | -1.13 | -1.75 | -1.13 | -1.66 | |
| Current ratio | 8.78 | 8.26 | 11.19 | 9.1 | 9.39 | |
| Interest coverage | 4.88K | 5.69K | 4.44K | 5.8K | 2.9K | |
| Income quality | 1 | 1 | 1 | 0.88 | 0.92 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0 | |
| Payout ratio | 0.03 | 0 | 0 | 1.39 | 0 | |
| Sales general and administrative to revenue | 0.1 | -0.09 | 0.02 | 0 | 0.06 | |
| Research and developement to revenue | 0.1 | 0.13 | 0.09 | 0.09 | 0.1 | |
| Intangibles to total assets | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.2 | -0.38 | -0.26 | -0.31 | -0.14 | |
| Capex to revenue | -0.08 | -0.2 | -0.1 | -0.11 | -0.06 | |
| Capex to depreciation | -2.11 | -4.45 | -2.27 | -2.7 | 0.84 | |
| Stock based compensation to revenue | -0.03 | -0.07 | 0 | 0 | 0 | |
| Graham number | 8.9 | 9.7 | 9.35 | 9.78 | 10.63 | |
| ROIC | 0.06 | 0.06 | 0.05 | 0.06 | 0.06 | |
| Return on tangible assets | 0.05 | 0.06 | 0.05 | 0.06 | 0.06 | |
| Graham Net | 4.35 | 4.43 | 4.82 | 4.35 | 4.59 | |
| Working capital | 4.03B | 4.24B | 4.77B | 4.46B | 4.68B | |
| Tangible asset value | 6.03B | 6.23B | 6.58B | 6.48B | 6.93B | |
| Net current asset value | 4B | 4.21B | 4.74B | 4.41B | 4.62B | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 513.02M | 535.29M | 548.01M | 634.17M | 681.83M | |
| Average payables | 207.47M | 189.85M | 161.86M | 150.13M | 138.93M | |
| Average inventory | 763.49M | 814.73M | 844.44M | 869.66M | 902.16M | |
| Days sales outstanding | 57.69 | 60.77 | 60.56 | 61.76 | 59.09 | |
| Days payables outstanding | 70.25 | 76.7 | 48.24 | 52.84 | 41.95 | |
| Days of inventory on hand | 273.43 | 364.37 | 278.74 | 306.82 | 307.86 | |
| Receivables turnover | 1.56 | 1.48 | 1.49 | 1.46 | 1.52 | |
| Payables turnover | 1.28 | 1.17 | 1.87 | 1.7 | 2.15 | |
| Inventory turnover | 0.33 | 0.25 | 0.32 | 0.29 | 0.29 | |
| ROE | 0.06 | 0.06 | 0.05 | 0.06 | 0.06 | |
| Capex per share | -0.09 | -0.19 | -0.12 | -0.14 | -0.07 |
300832.SZ Frequently Asked Questions
What is Shenzhen New Industries Biomedical Engineering Co., Ltd. stock symbol ?
Shenzhen New Industries Biomedical Engineering Co., Ltd. is a CN stock and trading under the symbol 300832.SZ
What is Shenzhen New Industries Biomedical Engineering Co., Ltd. stock quote today ?
Shenzhen New Industries Biomedical Engineering Co., Ltd. stock price is $63.55 today.
Is Shenzhen New Industries Biomedical Engineering Co., Ltd. stock public?
Yes, Shenzhen New Industries Biomedical Engineering Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 3.08M
- Market Capitalization 51.71B
- Employee 2.63K
- CEO Dr. Rao Wei
- Headquarters Shenzhen,CN
- IPO Date 2020-05-12
-
Website
https://www.snibe.com 
Shenzhen New Industries Biomedical Engineering Co., Ltd., a bio-medical company, engages in the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals and laboratories in China and internationally. It offers immunology, clinical chemistry, and integrated systems, as well as immunoassay and clinical chemistry reagent kits. The company was founded in 1995 and is based in Shenzhen, China.
